✨ Free AI Report
Pharvaris N.V.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Pharvaris N.V.
Company Research

Pharvaris N.V.: Business Overview, Financials & Competitive Analysis

Pharvaris N.V. scores 8/10 on the AskCyborg Cyborg Score (Strong). Leading pure-play oral therapy for rare bradykinin-mediated angioedema with strong clinical efficacy and adequate funding runway toward pivotal readouts. Phase 2 trials showed mean attacks reduced from 2.18 to 0.12 attacks/month (92.4% attack reduction) with median onset of symptom relief at 1.1 hours and 89.2% attack resolution at 24 hours.

What is Pharvaris N.V.'s industry? Pharvaris N.V. (pharvaris.com) operates in Biopharmaceuticals - Rare Diseases / Specialty Care. AskCyborg classifies Pharvaris N.V. under Biopharmaceuticals - Rare Diseases / Specialty Care in its company registry.

Pharvaris N.V. is a late-stage biopharmaceutical company focusing on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. Th...

8/ 10Strong

Cyborg Score thesis

Leading pure-play oral therapy for rare bradykinin-mediated angioedema with strong clinical efficacy and adequate funding runway...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Rare Diseases / Specialty Care
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Pharvaris N.V. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Pharvaris N.V.

AskCyborg analysts argue the bull and bear cases for Pharvaris N.V. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Pharvaris N.V. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Pharvaris N.V. Overview

Pro stress-test →

Pharvaris N.V. is a late-stage biopharmaceutical company focusing on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company aims to provide injectable-like efficacy and placebo-like tolerability with the convenience of oral therapy to prevent and treat angioedema attacks.

Strategic Profile

Pro stress-test →

Pharvaris is developing deucrictibant, a novel, potent, oral small-molecule bradykinin B2 receptor antagonist with two distinct formulations to address unmet needs in both on-demand (immediate-release capsule) and prophylactic (extended-release tablet) hereditary angioedema treatment. Expected pivotal readouts include CHAPTER-3 in H2 2026 and RAPIDe-3 in Q4 2025, with a validated kinin assay for biomarker measurement.

Competitive Landscape

Pro stress-test →

Key competitors in the bradykinin-mediated angioedema space include Xenon Pharmaceuticals, KalVista Pharmaceuticals, and Upstream Bio. Pharvaris differentiates through dual-formulation oral approach targeting both prophylactic and on-demand treatment paradigms, distinguishing from existing injectable therapies.

Industry Context

Pharvaris N.V. operates in Biopharmaceuticals - Rare Diseases / Specialty Care.

Key facts

Founded: 2015 · Headquarters: Zug, Switzerland · Market cap: $1.1B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Pharvaris N.V..

  • November 2025 ACAAI presentation demonstrated long-term safety with up to ~34 months of treatment, validated kinin biomarker assay, and rapid symptom relief (median 1.1 hours onset)
  • Positive Phase 2 data in both prophylaxis and on-demand studies support advancement to Phase 3 clinical development
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025ACAAI 2025 presentation: CHAPTER-1 extension showed 92.4% attack reduction over 34 months; RAPIDe-2 reported 1.1-hour median onset and 89.2% 24-hour resolution rates
  • July 2025Closed $201.2 million public offering managing cash runway into Q1-Q2 2027
  • +2 moreTrack every material event for Pharvaris N.V. as it happens. Explore monitoring →
Get alerted when Pharvaris N.V. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

GalidesivirCompeting investigational B2 antagonist programs for angioedema→KVD818Oral Factor XIIa inhibitor for hereditary angioedema→Firazyr (icatibant)Established injectable bradykinin B2 antagonist standard of care→

Compare Pharvaris N.V. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Pharvaris N.V. operates in Biopharmaceuticals - Rare Diseases / Specialty Care. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Rare Diseases / Specialty Care research →
NEW · MCP server

Ask your AI assistant about Pharvaris N.V.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Pharvaris N.V. and its top competitor on Cyborg Score”
“What did Pharvaris N.V. do this quarter?”
“Is Pharvaris N.V. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Pharvaris N.V. do?+
Pharvaris N.V. is a late-stage biopharmaceutical company focusing on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. Th...
What is Pharvaris N.V.'s Cyborg Score?+
Pharvaris N.V. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Pharvaris N.V.'s main competitors?+
Named competitors include Galidesivir, KVD818, Firazyr (icatibant). The full competitive landscape is in the AskCyborg report.
How can I get the full Pharvaris N.V. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Pharvaris N.V. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Pharvaris N.V. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - Rare Diseases research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Pharming Group N.V.